Mandate Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

October 29, 2018

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Vinge contributes to IUMI Eye

International Union of Marine Insurers (IUMI) is preparing for its first web based conference – Stockholm 2020 – of which Vinge is a proud sponsor. In the latest edition of IUMI Eye, published just in time for the conference, Vinge’s Paula Bäckdén and Sweden Insurance’s senior advisor Mikaela Tamm discuss the implications of waiving liability limitations.
September 15, 2020

Vinge – Best law firm for female business lawyers

Vinge has been awarded “Best Nordic Business Law Firm for Women” at the European Women in Business Law Awards which took place in London on 10 September. For the eighth time, Vinge has won the award as the law firm which has been most successful in relation to its gender equality work.
September 10, 2020

Clarification of the interpretation of ”nearest suitable railway station”

Road transport performed by Samskip Sia in Sweden has been confirmed to be within the framework of a permitted combined transport through a decision of the Administrative court of Falun in Sweden. The central question in the case was how to interpret the term “nearest suitable railway station”
June 30, 2020